Clinical Trial Update: The Efficacy and Safety of ARNI on the Outcome of Advanced Lung Cancer With Concurrent Hypertension [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update assessing the efficacy and safety of an angiotensin receptor-neprilysin inhibitor (ARNI) in patients with advanced lung cancer a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Lung Cancer

Drugs mentioned

• Entresto (sacubitril/valsartan)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Advanced Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING